| 来源类型 | Article |
| 规范类型 | 评论 |
| Drug quality and global trade | |
| Aparna Mathur; Roger Bate; Amir Attaran; Ginger Zhe Jin | |
| 发表日期 | 2014-10-09 |
| 出版年 | 2014 |
| 语种 | 英语 |
| 摘要 | There is a perception amongst pharmaceutical experts that some Indian manufacturers and/or their distributors segment the global medicine market into portions that are served by different quality medicines. This column finds that drug quality is poorer among Indian-labelled drugs purchased inside African countries than among those purchased inside India or middle-income countries. Substandard drugs – non-registered in Africa and containing insufficient amounts of the active ingredient – are the biggest driver of this quality difference. Read the full article at VoxEU.org. |
| 主题 | Health Care |
| 标签 | drug safety ; drugs ; India ; Pharmaceuticals |
| URL | https://www.aei.org/articles/drug-quality-global-trade/ |
| 来源智库 | American Enterprise Institute (United States) |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/257503 |
| 推荐引用方式 GB/T 7714 | Aparna Mathur,Roger Bate,Amir Attaran,et al. Drug quality and global trade. 2014. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
